Supplemental Protection Certificates (SPC) can extend a patent right for a maximum of five years. A six-month additional extension is available in accordance with Regulation (EC) No 1901/2006 if the SPC relates to a medicinal product for children for which data has been submitted according to a Pediatric Investigation Plan (PIP). PIPs are required to ... Read More
Ticagrelor (trade name Brilinta, Brilique, and Possia) is a blockbuster drug produced by AstraZeneca with total sales of $1,079m in 2017. Ticagrelor: is a platelet aggregation inhibitor and is used for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation.
Dear Sir and Madam, Dear clients: We are pleased to announce that IP2 Patentanwalts GmbH is in the process of opening the next chapter in its history: As of January 1, 2019, we announce the association with our US colleagues Dilworth & Barrese, LLP. With this step, we will be able to offer all aspects ... Read More
Genetic Engineering and Molecular Biomedicine belong to the most fascinating and fastest developing areas in Life Sciences and represent key areas of competence for IP2. Therefore our scientific advisors Martin Fabry and Julia Betzin comment on recent developments in these fields.
Sofusbovir is a substance from the group of nucleotide prodrugs, which has been successfully marketed by the US pharmaceutical company Gilead since 2013 as a medicament under the brand name „SOVALDI“. Sofosbuvir inhibits the RNA-dependent enzyme NS5B polymerase, which plays an important role in the replication of specific viruses. Thus, the substance is effective against ... Read More
LAWYER MONTHLY is one the leading law journals with a strong editorial focus on legal news from across key practices areas, jurisdictions and sectors, both from established and emerging markets. It was therefore an honor being asked to comment on trends and expected changes with regard to IP law firms.
In recent years, advances in the CRISPR-Cas9 technology lead to a revolution in genome engineering across the world. The easy to use components of the technique facilitate accurate and fast genomic manipulation. Successful applications have been reported in human cells as well as embryos. This technology presents modern medicine with the possibility to treat diseases ... Read More
The world’s pre-eminent IP strategists have been named in the latest edition of IAM Strategy 300 – The World’s Leading IP Strategists, and after 2017 for the second time Bernd Fabry and IP2 have been awarded.